MacroGenics - MGNX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.11
  • Forecasted Upside: 139.97%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$3.38
▲ +0.04 (1.20%)

This chart shows the closing price for MGNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MacroGenics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGNX

Analyst Price Target is $8.11
▲ +139.97% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for MacroGenics in the last 3 months. The average price target is $8.11, with a high forecast of $14.00 and a low forecast of $4.00. The average price target represents a 139.97% upside from the last price of $3.38.

This chart shows the closing price for MGNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 polled investment analysts is to hold stock in MacroGenics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/9/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/7/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/5/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
2/3/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/3/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/1/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
9/30/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/30/2024

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/18/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
9/16/2024Evercore ISIUpgradeStrong-Buy
8/21/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
8/15/2024CitigroupLower TargetBuy ➝ Buy$16.00 ➝ $14.00
8/7/2024BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$8.00 ➝ $5.00
8/1/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00
8/1/2024BTIG ResearchDowngradeBuy ➝ Neutral
7/31/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$16.00 ➝ $8.00
7/31/2024B. RileyDowngradeBuy ➝ Neutral$18.00 ➝ $5.00
7/31/2024GuggenheimDowngradeBuy ➝ Neutral
7/29/2024BarclaysLower TargetOverweight ➝ Overweight$14.00 ➝ $9.00
5/24/2024BTIG ResearchLower TargetBuy ➝ Buy$24.00 ➝ $9.00
5/13/2024HC WainwrightLower TargetNeutral ➝ Neutral$16.00 ➝ $4.00
5/10/2024BarclaysLower TargetOverweight ➝ Overweight$25.00 ➝ $14.00
5/10/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$22.00 ➝ $16.00
5/10/2024BMO Capital MarketsDowngradeOutperform ➝ Market Perform$24.00 ➝ $8.00
5/10/2024Stifel NicolausDowngradeBuy ➝ Hold$29.00 ➝ $7.00
5/10/2024TD CowenDowngradeBuy ➝ Hold
4/26/2024B. RileyInitiated CoverageBuy$25.00
4/9/2024TD CowenUpgradeHold ➝ Buy
4/4/2024JMP SecuritiesReiterated RatingMarket Outperform
3/4/2024BTIG ResearchBoost TargetBuy ➝ Buy$12.00 ➝ $24.00
2/29/2024BarclaysBoost TargetOverweight ➝ Overweight$12.00 ➝ $23.00
2/14/2024HC WainwrightDowngradeBuy ➝ Neutral$12.00 ➝ $14.00
1/24/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00
12/20/2023CitigroupUpgradeNeutral ➝ Buy$7.00 ➝ $13.00
11/27/2023Stifel NicolausReiterated RatingBuy ➝ Buy$17.00
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $12.00
11/7/2023GuggenheimUpgradeNeutral ➝ Buy$12.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$14.00
5/11/2023JMP SecuritiesBoost Target$8.00 ➝ $10.00
4/3/2023HC WainwrightReiterated RatingBuy$14.00
3/21/2023BTIG ResearchBoost TargetBuy$6.00 ➝ $12.00
3/20/2023CitigroupBoost Target$7.00 ➝ $8.00
3/20/2023HC WainwrightBoost Target$12.00 ➝ $14.00
3/17/2023GuggenheimReiterated RatingBuy ➝ Neutral
3/16/2023JMP SecuritiesReiterated RatingMarket Outperform$8.00
3/9/2023Stifel NicolausBoost Target$15.00 ➝ $17.00
1/19/2023JMP SecuritiesLower TargetMarket Outperform$18.00 ➝ $8.00
11/23/2022CitigroupDowngradeBuy ➝ Neutral$16.00 ➝ $7.00
11/22/2022GuggenheimUpgradeNeutral ➝ Buy$12.00
11/22/2022CowenDowngradeOutperform ➝ Market Perform
11/22/2022CowenDowngradeOutperform ➝ Market Perform
11/14/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$5.70 ➝ $16.00
11/7/2022HC WainwrightBoost TargetBuy$11.00 ➝ $12.00
10/18/2022HC WainwrightBoost TargetBuy$10.00 ➝ $11.00
9/12/2022HC WainwrightLower TargetBuy$35.00 ➝ $10.00
8/29/2022CitigroupBoost TargetBuy$13.00 ➝ $16.00
8/15/2022BarclaysLower Target$8.00
8/9/2022Leerink PartnersLower TargetOutperform$15.00 ➝ $12.00
8/9/2022BarclaysLower TargetOverweight$18.00 ➝ $8.00
7/19/2022BTIG ResearchSet Target$6.00
7/18/2022Sumitomo Mitsui Financial GroupDowngradeOutperform ➝ Neutral$5.00
7/12/2022JMP SecuritiesLower TargetMarket Outperform$24.00 ➝ $20.00
7/11/2022BTIG ResearchLower Target$6.00
7/11/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$31.00 ➝ $4.00
5/4/2022GuggenheimDowngradeBuy ➝ Neutral
5/4/2022HC WainwrightLower Target$41.00 ➝ $35.00
2/28/2022CitigroupUpgradeNeutral ➝ Buy$23.00 ➝ $21.00
2/25/2022BarclaysLower Target$35.00 ➝ $18.00
2/25/2022Leerink PartnersLower TargetOutperform$40.00 ➝ $23.00
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$31.00
2/4/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$40.00
11/17/2021GuggenheimInitiated CoverageBuy$30.00
11/3/2021JMP SecuritiesLower TargetMarket Outperform$39.00 ➝ $38.00
10/19/2021JMP SecuritiesInitiated CoverageOutperform$39.00
9/20/2021HC WainwrightReiterated RatingBuy$41.00
9/19/2021Leerink PartnersReiterated RatingBuy
7/27/2021HC WainwrightReiterated RatingBuy$41.00
6/17/2021HC WainwrightReiterated RatingBuy
6/16/2021BTIG ResearchInitiated CoverageBuy
6/7/2021WedbushLower TargetOutperform$39.00 ➝ $34.00
4/30/2021Leerink PartnersBoost TargetOutperform$37.00 ➝ $40.00
4/30/2021HC WainwrightBoost TargetBuy$36.00 ➝ $41.00
4/26/2021Morgan StanleyBoost TargetUnderweight$16.00 ➝ $17.00
4/19/2021Morgan StanleyBoost TargetUnderweight$15.00 ➝ $16.00
3/12/2021BarclaysUpgradeUnderweight ➝ Overweight$14.00 ➝ $40.00
3/4/2021Morgan StanleyBoost TargetUnderweight$14.00 ➝ $15.00
2/26/2021Morgan StanleyBoost TargetUnderweight$14.00 ➝ $15.00
12/22/2020HC WainwrightReiterated RatingBuy$36.00
12/17/2020BarclaysBoost TargetUnderweight$8.00 ➝ $14.00
11/13/2020Morgan StanleyBoost TargetUnderweight$13.00 ➝ $14.00
11/5/2020Leerink PartnersLower TargetOutperform$38.00 ➝ $37.00
10/13/2020Morgan StanleyBoost TargetUnderweight$12.00 ➝ $13.00
9/21/2020Leerink PartnersBoost TargetOutperform$35.00 ➝ $38.00
8/3/2020CitigroupDowngradeBuy ➝ Neutral$25.00 ➝ $26.00
7/31/2020Morgan StanleyBoost TargetUnderweight$11.00 ➝ $12.00
7/31/2020HC WainwrightReiterated RatingBuy$40.00
7/15/2020Morgan StanleyBoost TargetUnderweight$6.00 ➝ $11.00
6/2/2020CitigroupBoost Target$15.00 ➝ $25.00
6/1/2020GuggenheimUpgradeNeutral ➝ Buy
5/29/2020Leerink PartnersBoost TargetOutperform$15.00 ➝ $27.00
5/29/2020Stifel NicolausBoost TargetBuy$21.00 ➝ $36.00
5/28/2020BTIG ResearchBoost TargetBuy$23.00 ➝ $35.00
5/26/2020HC WainwrightBoost TargetBuy$22.00 ➝ $40.00
5/17/2020NomuraReiterated RatingBuy$50.00
5/14/2020WedbushBoost TargetOutperform$16.00 ➝ $28.00
5/12/2020Credit Suisse GroupBoost TargetOutperform$13.00 ➝ $30.00
5/6/2020WedbushReiterated RatingOutperform
5/6/2020Credit Suisse GroupLower TargetOutperform$17.00 ➝ $13.00
5/6/2020Leerink PartnersLower TargetOutperform$16.00 ➝ $15.00
5/6/2020HC WainwrightBoost TargetBuy$18.00 ➝ $22.00
3/4/2020BarclaysInitiated CoverageUnderweight$8.00
3/2/2020Credit Suisse GroupLower TargetOutperform$26.00 ➝ $17.00
2/26/2020HC WainwrightReiterated RatingBuy$18.00
2/26/2020Stifel NicolausLower TargetBuy$21.00 ➝ $20.00
2/26/2020CitigroupLower TargetBuy$18.00 ➝ $15.00
1/21/2020WedbushBoost TargetOutperform$14.00 ➝ $16.00
12/20/2019HC WainwrightReiterated RatingBuy$18.00
12/18/2019Cantor FitzgeraldInitiated CoverageOverweight$17.00
12/12/2019BTIG ResearchReiterated RatingBuy ➝ Positive$23.00
12/12/2019Nomura SecuritiesReiterated RatingBuy$50.00
12/10/2019HC WainwrightReiterated RatingBuy$18.00
12/10/2019CowenReiterated RatingBuy
11/21/2019Morgan StanleyDowngradeEqual ➝ Equal Weight$17.00 ➝ $6.00
11/20/2019GuggenheimInitiated CoverageHold
11/7/2019CitigroupLower TargetBuy$39.00 ➝ $18.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/3/2024
  • 9 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/3/2024
  • 5 very positive mentions
  • 27 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
6/2/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/2/2024
  • 3 very positive mentions
  • 35 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/1/2024
  • 15 very positive mentions
  • 100 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
8/31/2024
  • 4 very positive mentions
  • 82 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/30/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/30/2024

Current Sentiment

  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
MacroGenics logo
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $3.38
Low: $3.22
High: $3.53

50 Day Range

MA: $3.54
Low: $3.00
High: $4.28

52 Week Range

Now: $3.38
Low: $2.95
High: $21.88

Volume

505,523 shs

Average Volume

1,495,668 shs

Market Capitalization

$211.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.08

Frequently Asked Questions

What sell-side analysts currently cover shares of MacroGenics?

The following sell-side analysts have issued stock ratings on MacroGenics in the last twelve months: B. Riley, Barclays PLC, BMO Capital Markets, BTIG Research, Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, JMP Securities, Stifel Nicolaus, StockNews.com, TD Cowen, and TheStreet.
View the latest analyst ratings for MGNX.

What is the current price target for MacroGenics?

9 Wall Street analysts have set twelve-month price targets for MacroGenics in the last year. Their average twelve-month price target is $8.11, suggesting a possible upside of 142.8%. Citigroup Inc. has the highest price target set, predicting MGNX will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $4.00 for MacroGenics in the next year.
View the latest price targets for MGNX.

What is the current consensus analyst rating for MacroGenics?

MacroGenics currently has 7 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MGNX, but not buy more shares or sell existing shares.
View the latest ratings for MGNX.

What other companies compete with MacroGenics?

How do I contact MacroGenics' investor relations team?

MacroGenics' physical mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company's listed phone number is (301) 251-5172 and its investor relations email address is [email protected]. The official website for MacroGenics is www.macrogenics.com. Learn More about contacing MacroGenics investor relations.